Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VTRS Stock Forecast 2025-2026
$8.50
Current Price
$9.98B
Market Cap
Buy 3
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to VTRS Price Targets
+64.7%
To High Target of $14.00
+52.9%
To Median Target of $13.00
-5.9%
To Low Target of $8.00
VTRS Price Momentum
-3.8%
1 Week Change
+5.9%
1 Month Change
-18.3%
1 Year Change
-31.7%
Year-to-Date Change
-37.3%
From 52W High of $13.55
+24.1%
From 52W Low of $6.85
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Viatris (VTRS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VTRS and similar high-potential opportunities.
Latest VTRS Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, VTRS has a neutral consensus with a median price target of $13.00 (ranging from $8.00 to $14.00). The overall analyst rating is Buy (6.9/10). Currently trading at $8.50, the median forecast implies a 52.9% upside. This outlook is supported by 3 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 64.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VTRS Analyst Ratings
3
Buy
5
Hold
1
Sell
VTRS Price Target Range
Low
$8.00
Average
$13.00
High
$14.00
Current: $8.50
Latest VTRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VTRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | Jefferies | Glen Santangelo | Buy | Maintains | $13.00 |
| Mar 5, 2025 | Piper Sandler | David Amsellem | Neutral | Reiterates | $10.00 |
| Feb 28, 2025 | Barclays | Balaji Prasad | Underweight | Maintains | $9.00 |
| Feb 28, 2025 | B of A Securities | Jason Gerberry | Underperform | Maintains | $10.00 |
| Dec 6, 2024 | Piper Sandler | David Amsellem | Neutral | Reiterates | $14.00 |
| Nov 8, 2024 | Barclays | Balaji Prasad | Underweight | Maintains | $12.00 |
| Jul 19, 2024 | Jefferies | Glen Santangelo | Buy | Reinstates | $15.00 |
| Mar 28, 2024 | Piper Sandler | David Amsellem | Neutral | Reiterates | $13.00 |
| Nov 22, 2023 | Piper Sandler | David Amsellem | Neutral | Maintains | $11.00 |
| Oct 23, 2023 | B of A Securities | Jason Gerberry | Underperform | Downgrade | $9.00 |
| Jun 23, 2023 | Barclays | Balaji Prasad | Underweight | Downgrade | $11.00 |
| Apr 25, 2023 | Barclays | Balaji Prasad | Equal-Weight | Downgrade | $11.00 |
| Apr 24, 2023 | Barclays | Balaji Prasad | Equal-Weight | Downgrade | $11.00 |
| Feb 28, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $16.00 |
| Feb 17, 2023 | BMO Capital | Gary Nachman | Market Perform | Downgrade | $14.00 |
| Feb 1, 2023 | Barclays | Balaji Prasad | Overweight | Maintains | $15.00 |
| Jan 27, 2023 | Jefferies | Glen Santangelo | Buy | Upgrade | $15.00 |
| Nov 15, 2022 | JP Morgan | Chris Schott | Neutral | Maintains | $14.00 |
| Nov 10, 2022 | UBS | Ashwani Verma | Neutral | Upgrade | $12.00 |
| Nov 8, 2022 | Piper Sandler | David Amsellem | Neutral | Upgrade | $10.00 |
Viatris Inc. (VTRS) Competitors
The following stocks are similar to Viatris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Viatris Inc. (VTRS) Financial Data
Viatris Inc. has a market capitalization of $9.98B with a P/E ratio of 235.8x. The company generates $14.33B in trailing twelve-month revenue with a -26.4% profit margin.
Revenue growth is -11.2% quarter-over-quarter, while maintaining an operating margin of +5.7% and return on equity of -21.3%.
Valuation Metrics
Market Cap
$9.98B
Enterprise Value
$23.41B
P/E Ratio
235.8x
PEG Ratio
3.2x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-11.2%
Gross Margin
+35.7%
Operating Margin
+5.7%
Net Margin
-26.4%
EPS Growth
-11.2%
Financial Health
Cash/Price Ratio
+10.0%
Current Ratio
1.7x
Debt/Equity
92.4x
ROE
-21.3%
ROA
+2.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Viatris Inc. (VTRS) Business Model
About Viatris Inc.
What They Do
Produces and markets a wide range of pharmaceuticals.
Business Model
The company generates revenue by producing and selling a diverse portfolio of pharmaceutical products, including brand-name drugs, generics, and biosimilars. By merging the strengths of Mylan and Upjohn, Viatris enhances its operational efficiencies and market reach, focusing on providing affordable medications to various therapeutic areas worldwide.
Additional Information
Viatris operates in multiple sectors such as cardiovascular, oncology, dermatology, and infectious diseases. The company emphasizes sustainability and access to medicines, particularly for underserved populations, supported by a robust supply chain and a strong global presence. Its mission is to empower individuals to lead healthier lives at every stage.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
32,000
CEO
Mr. Scott Andrew Smith Ph.D.
Country
United States
IPO Year
1980
Website
www.viatris.comViatris Inc. (VTRS) Latest News & Analysis
Latest News
Quick Summary
Investors in Viatris Inc. (NasdaqGS: VTRS) have until June 3, 2025, to file lead plaintiff applications in a class action lawsuit for securities bought between August 8, 2024, and February 26, 2025.
Why It Matters
The deadline for lead plaintiff applications in a class action lawsuit against Viatris may impact investor sentiment, stock price, and potential liabilities for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Viatris Inc. (NASDAQ: VTRS) is facing a class action securities lawsuit, as notified by Levi & Korsinsky, LLP on May 22, 2025. Investors should monitor potential implications.
Why It Matters
A class action lawsuit against Viatris could lead to financial liabilities and affect stock performance, raising concerns over the company's governance and future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investors in Viatris Inc. (NASDAQ: VTRS) who experienced losses may explore potential recovery options under federal securities laws. More information is available through the provided link.
Why It Matters
The news indicates potential legal issues for Viatris Inc., which could lead to financial liabilities and impact stock performance, signaling risk for current and prospective investors.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
A class action complaint has been filed against Viatris, Inc. (NASDAQ: VTRS) for alleged securities violations from August 8, 2024, to February 26, 2025. Investors may seek legal options.
Why It Matters
The lawsuit against Viatris could lead to financial penalties or reputational damage, affecting stock prices and investor sentiment. Legal challenges often signal potential volatility.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) for alleged federal securities law violations, affecting investors who acquired shares between August 8, 2024, and February 26, 2025.
Why It Matters
The class action lawsuit against Viatris could lead to financial penalties, impacting stock prices and investor confidence, while raising concerns about the company’s compliance and governance.
Source: Accesswire
Market Sentiment:
Neutral
Class Action Alert: Levi & Korsinsky Reminds Viatris (VTRS) Investors of June 3, 2025 Deadline
2 days ago
Quick Summary
Investors in Viatris Inc. (NASDAQ: VTRS) who experienced losses may explore potential recovery options under federal securities laws. More information is available through a provided link.
Why It Matters
The news signals potential legal issues for Viatris Inc., which could impact its stock performance and investor confidence, possibly leading to price volatility.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About VTRS Stock
What is Viatris Inc.'s (VTRS) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Viatris Inc. (VTRS) has a median price target of $13.00. The highest price target is $14.00 and the lowest is $8.00.
Is VTRS stock a good investment in 2025?
According to current analyst ratings, VTRS has 3 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $8.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VTRS stock?
Wall Street analysts predict VTRS stock could reach $13.00 in the next 12 months. This represents a 52.9% increase from the current price of $8.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viatris Inc.'s business model?
The company generates revenue by producing and selling a diverse portfolio of pharmaceutical products, including brand-name drugs, generics, and biosimilars. By merging the strengths of Mylan and Upjohn, Viatris enhances its operational efficiencies and market reach, focusing on providing affordable medications to various therapeutic areas worldwide.
What is the highest forecasted price for VTRS Viatris Inc.?
The highest price target for VTRS is $14.00 from David Amsellem at Piper Sandler, which represents a 64.7% increase from the current price of $8.50.
What is the lowest forecasted price for VTRS Viatris Inc.?
The lowest price target for VTRS is $8.00 from at , which represents a -5.9% decrease from the current price of $8.50.
What is the overall VTRS consensus from analysts for Viatris Inc.?
The overall analyst consensus for VTRS is neutral. Out of 12 Wall Street analysts, 3 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $13.00.
How accurate are VTRS stock price projections?
Stock price projections, including those for Viatris Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 12:32 AM UTC